Clinical Trial · NCT02747290

68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients

Overview

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-BBN-RGD in prostate cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Zhaohui Zhu, MD.PhD. (CONTACT)

13611093752@163.com

+86 10 69154196

Jingjing Zhang, MD.PhD. (CONTACT)

zhangjingjingtag@163.com

+86 10 69155513

Fang Li, MD. (STUDY_CHAIR)

ClinicalTrials.gov

NCT02747290

Drug / Compound

NOTA-BBN-RGD

Isotope(s):

Target(s):

GRPR

Ligand Class: Peptides

Chelator: NOTA

Linker: glutamate

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

The exclusion criteria included claustrophobia, kidney or liver failure, and inability to fulfill the study.